May 2023 Top Biopharma Deal: Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066

Jun 1, 2023 | Deal of the Month

May 2023 Top Biopharma Deal Upfront
Cellular Biomedicine development and commercialization deal with Janssen for C-CAR039 and C-CAR066

Highlighted Deal Financial Comps

Date Announced:

May 3, 2023

Total Deal Value:

$245M + Milestones

Upfront Cash:


Upfront Equity:


Option Payments:


Total Milestones:

Undisclosed dev., reg., and sales milestones



Cost & Profit Split:


Deal Synopsis

The Asset:

Preclinical C-CAR039, an anti-CD19 & CD20 bi-specific CAR-T therapy, and C-CAR066, an anti-CD20 CAR-T for the treatment of Non-Hodgkin Lymphoma (NHL)

Deal Structure:

Dev and Commercial License

Partnership Features:

Collaborative Development, No Shared Cost , Options to Add Products, TAs, and/or Territories , Supply by Licensor

Deal Details:

  • Cellular Biomedicine granted Janssen exclusive, worldwide rights (excluding China) for the development and commercialization of C-CAR039 and C-CAR066 CAR-T therapies for Non-Hodgkin Lymphoma.
  • Janssen has the option to develop therapies in China before the BLA application.
  • Cellular will also transfer and supply the IND and studies with viral vector and plasmid related to C-CAR039 and C-CAR066.
  • Cellular Biomedicine will receive an upfront payment of $245M, along with undisclosed potential milestone payments and royalties.

Last Month:

Congrats to Cellular Biomedicine and Janssen for landing DealForma’s May 2023 Top Biopharma Deal. Last month’s Deal of the Month was DualityBio – BioNTech for DB-1303 and DB-1311. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.

We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting to schedule your personalized demo.


Licensing Deals


Funding Rounds




Company Profiles


Other Deals


Drug Sales Figures

All of this by stage, disease indication, modality, target...

More Research by DealForma

Neurology Venture Activity Through Q2 2023

Neurology Venture Activity Through Q2 2023

Quarterly venture investment activity into neurology focused biopharma companies is back to pre-2020 level. This is no surprise given the investment slowdowns across all therapy area and broader life sciences. The drop seems to have stabilized however, and emerging...